Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s.
Pindolol was granted FDA approval on 3 September 1982.
Pindolol is indicated in the management of hypertension. In Canada, it is also indicated in the prophylaxis of angina.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.